Venetoclax combined with chidamide and decitabine successfully induced remission in relapsed/refractory classical Hodgkin lymphoma: a case report and literature review
Most patients with classical Hodgkin lymphoma (cHL) can achieve long-term survival with frontline combination chemotherapy and radiation therapy, but approximately 10%-30% of patients will develop relapsed/refractory (R/R) disease. High-dose chemothera…